AUTHORS
Jing Christine Ye, M.D., MSc, Philip Boonstra2, Jeffrey A. Zonder, MD3, Matthew J. Pianko, MD4, Larry D Anderson Jr, MD, PhD5, Brea Lipe, MD6, Andrew Kin, MD7, Daniel Frederick Boyer, MD, PhD8, Moshe Talpaz, MD9, Erica Campagnaro, MD10
AFFILIATIONS
1 MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
2 University of Michigan, Ann Arbor, United States
3 Karmanos Cancer Institute, Detroit, United States
4 University of Michigan, Ann Arbor, United States
5 UTSW, Dallas, United States
6 University of Rochester, Rochester, United States
7 Karmanos Cancer Institute, Detroit, United States
8 University of Michigan, Ann Arbor, United States
9 University of Michigan, Ann Arbor, United States
10 University of Michigan, Ann Arbor, United States
ABSTRACT
Introduction: MRD-guided adaptive strategies represent a paradigm shift, aiming to optimize outcomes while minimizing treatment toxicity. We investigated an MRD driven approach in newly diagnosed multiple myeloma (NDMM) patients (pts) using daratumumab-lenalidomide-dexamethasone (DRd) induction with bortezomib-intensified consolidation reserved for MRD positive pts, designed to reduce toxicity while preserving efficacy in both transplant-eligible (TE) and transplant-not-eligible (TNE) pts. (NCT04140162)
Methods: This multicenter, single arm phase 2 trial enrolled TE and TNE pts with NDMM. Induction (C1-6, 28-day cycle) comprised daratumumab (Dara) IV or SC, lenalidomide (Len) 25mg D1-21, dexamethasone (Dex) 40mg weekly. TE pts underwent stem cell collection at C4-6. After C6, pts achieving ≥VGPR underwent MRD1 assessment (10-6 by NGS plus PET/CT). MRD1-negative pts proceeded directly to maintenance therapy (Dara-Len for 1yr, then Len alone). MRD1-positive pts received consolidation (C7-9) with the addition of bortezomib (1.5 mg/m2 SC, on D1, 8, 15, 22) before maintenance. MRD2 and MRD3 were assessed post-consolidation and after 1yr of maintenance. PET/CT was conducted at the same MRD time points. TE pts who were MRD2-positive could proceed to ASCT.
Primary endpoints were MRD negativity (10-6) post-induction (MRD1) and post-consolidation (MRD2). Study success requires an observed MRD ever-negativity rate of 9/50 (18%), providing 0.83 power to detect a true rate of 23% at a one-sided type I error of 0.055. Secondary endpoints were OS, PFS, safety and QoL (EQ-5D VAS).
Results: Of 57 pts enrolled, 50 were evaluable for efficacy and 56 for safety (data cut 25 May 2026). Median age was 65 yrs (44-77); 46% females; 18% Black; R-ISS I/II/III 58%/30%/12%. Among the 50 efficacy-evaluable pts, 8 were TNE and 42 TE; 7 TE pts (16.7%) elected ASCT after consolidation.
The trial met its primary objective: 15 pts (30%; 95% CI 19.1%-43.8%) achieved MRD-negativity at 10-6 by MRD2. 10 pts (10/45, 22.2%) converted from MRD1-positive to MRD2-negative, demonstrating response deepening under the adaptive strategy. VGPR or better was achieved by 44 pts (88%; 95% CI 76.2%-94.4%).
At a median follow-up of 40.5 mo (IQR 30.9-44.5), median PFS and OS were not reached; 3yr PFS was 77.1% (95% CI 66.1, 90.0); and 3yr OS 89.3% (95% CI 80.8, 98.6).
The regimen was well tolerated. Grade ≥3 TRAEs occurring in ≥5% of pts were neutropenia (21.4%), lymphopenia (8.9%), and diarrhea (5.4%). Two pts (3.6%) discontinued for TRAEs. One pt (1.8%) developed AML (without ASCT). Five treatment-unrelated deaths occurred. Additional details will be provided at the presentation.
QoL improved during treatment. Model-predicted EQ-5D VAS (0-100 scale, higher is better) increased early and then plateaued, with estimated mean increases of 6.3 points (95% CrI 3.1, 9.7) at 6 months and 8.0 points (95% CrI 4.0, 12.1) at 1 year after start of treatment. Peripheral neuropathy assessment across eleven domains (0-4 scale, higher is worse) showed mild increases at 1 year from baseline in numbness (hands +0.30, 95% CrI 0.09, 0.60; feet +0.81, 95% CrI 0.47, 1.2) and discomfort (hands +0.20, 95% CrI 0.06, 0.50; feet +0.66, 95% CrI 0.37, 1.01); with improvement in weakness (-0.26, 95% CrI -0.52, -0.03), and no clinically or statistically significant changes in the remaining neuropathy measures.
Conclusions: This MRD-driven adaptive strategy, DRd induction with bortezomib consolidation reserved for MRD positive pts, converted MRD positivity to negativity at the 10-6 level plus imaging in a subset of pts with NDMM. With most TE pts deferring ASCT, 3yr PFS and OS were encouraging. The regimen was well tolerated, with significant improvement in patient reported QoL and minimal neuropathy. These data support further evaluation of MRD guided treatment adaptation as a strategy to improve patient outcomes while minimizing treatment burden.
DISCLOSURES
Jing Christine Ye, M.D., MSc: Sanofi - Honoraria; Johnson & Johnson - Research Funding; J&J - Research Funding; Bristol Myers Squibb - Research Funding; Pfizer - Membership on a Board/Advisory Committee; J&J - Membership on a Board/Advisory Committee